AIPLA Comments on FDA Biosimilars Draft Guidances

May 24, 2012

File Downloads

All documents are in PDF format.

While the Food and Drug Administration’s role in the scientific regulation of biologic drugs is generally outside this primary interest, implementation of the new abbreviated regulatory pathway for biosimilar products authorized under the Biologics Price Competition and Innovation Act of 2009 (BPCIA) contains some aspects that impact intellectual property rights, including patents, trademarks, trade secrets, regulatory exclusivity, and IP litigation.

In view of this impact, AIPLA provides comments on those aspects of the Draft Guidances that more or less directly impact intellectual property rights, and therefore impact our membership. Specifically, AIPLA provides comments on three issues: (1) definition of “protein (except any chemically synthesized polypeptide)”; (2) molecules having a changed amino acid sequence compared with the reference product; and (3) publication of exclusivity expiration dates.

Current Status

 

Upcoming Events

  • 2025 Women in IP Law Global Networking Event

    April 3, 2025

    The annual Global Networking Event connects intellectual property practitioners from around the world for a day of networking, education, and creating meaningful connections. This year’s theme, Innovation and Collaboration, is an opportunity for the AIPLA Women in IP Law Committee to come together and discuss how women drive innovation and foster collaboration in their workplace.
  • World IP Day 2025

    April 30, 2025 4:00 PM to 7:00 PM

    Join AIPLA and partner organizations on April 30 in Washington, DC, for a special three-hour program to celebrate World Intellectual Property Day 2025. This annual international event is an opportunity to learn about the role that intellectual property (IP) rights play in encouraging innovation and creativity. The theme of this year’s celebration is “IP and Music: Feel the Beat of IP.”